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Summary Data from the Cancer Registries of the Swiss Cantons of Vaud and Neuchatel were analysed to
examine possible associations between skin cancers (including basal cell carcinoma, BCC), non-Hodgkin's
lymphomas (NHL) and chronic lymphocytic leukaemias (CLL). Between 1974 and 1993, 1767 cases of NHL,
351 of CLL, 1678 of cutaneous malignant melanoma (CMM), 4131 of squamous cell carcinoma (SCC) and
10 575 of BCC were registered, and contributed to a total of 120 103 person -years at risk. Following NHL, 36
cases of SCC were registered compared with 5.1 expected, corresponding to a standardised incidence ratio
(SIR) of 7.0 (95% confidence interval, CI, 4.9-9.7); 37 cases of BCC were observed compared with 10.2
expected (SIR = 3.6; 95% CI 2.6-5.0). Following CLL, nine cases of SCC were observed compared with 1.8
expected (SIR=5.0; 95% CI 2.3-9.5) and nine cases of BCC were observed compared with 3.3 expected
(SIR = 2.7; 95% CI 1.2- 5.2). After SCC, 23 cases at NHL were observed compared with 9.0 expected
(SIR=2.6; 95% CI 1.6-3.8); after BCC, 43 cases of NHL were registered compared with 22.5 expected
(SIR= 1.9; 95% CI 1.4-2.6); and after CMM, four cases of NHL were observed compared with 2.0 expected
(SIR=2.0). No significant excess of CLL was recorded following skin cancer, but the absolute numbers were
small and the SIR was above unity. The findings of this study, conducted in populations with a high level of
ascertainment and registration of skin cancers, confirm an excess of skin cancers including BCC, following
NHL and CLL, and an excess of NHL following skin cancers. This may be related to shared aetiological
factors such as U.V. radiation and associated immunosuppression. Individual-based data on the relationship
between U.V. exposure and lymphoid neoplasms are needed to clarify the issue.
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The incidence of non-Hodgkin's lymphomas (NHL) and of
the related chronic lymphocytic leukaemias (CLL) has
substantially increased over the last few decades in most
areas of the world (Devesa and Fears, 1992; Hartge and
Devesa, 1992; Carli et al., 1994; Hartge et al., 1994; Levi et
al., 1995a; Hjalgrim et al., 1996). A proportion of this
increase is due to improved diagnosis and certification, but
this alone cannot adequately explain such a systematic and
substantial rise.
Immunodepression has been related to lymphomas, and an
immunodepressant effect of U.V. radiation has been reported
in experimental conditions (Hartge and Devesa, 1992;
Cartwright et al., 1994; Doll, 1996). Furthermore, a few
studies from the Nordic countries, North America and The
Netherlands have reported excess incidence of melanoma and
non-melanomatous skin cancers following NHL or CLL, and
of NHL or CLL following skin cancer (Travis et al., 1992,
1993; Adami et al., 1995; Hall et al., 1995; Frisch and
Melbye, 1995). The evidence, however, is not totally
consistent as no excess of NHL was observed after
melanoma in Denmark (Swerdlow et al., 1995). In addition,
ecological studies on populations in the UK (Bentham, 1996)
and on a worldwide scale (McMichael and Giles, 1996), but
not within the United States (Hartge et al., 1996), are
suggestive of a shared influence of U.V. exposure (on a
population level) on NHL and skin neoplasms.
In a systematic analysis of multiple primary cancers in
Vaud, Switzerland, between 1974 and 1989 (Levi et al., 1993),
an excess of non-melanomatous skin cancer was observed
after NHL and leukaemias in both sexes. We decided,
therefore, to update the analysis with specific focus on
various histotypes of skin cancer and lymphoid neoplasms.
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This was made possible by specific attention to identification
and registration of various histotypes of skin cancer,
including squamous cell carcinoma (SCC), basal cell
carcinoma (BCC) and cutaneous malignant melanoma
(CMM) (Levi et al., 1995b).
Materials and methods
The present analysis is based on the Vaud and Neuchatel
Cancer Registries files, which include information concerning
incident cases of malignant neoplasms in these cantons
(whose populations, according to the 1990 census, were
about 600 000 and 160 000 respectively; Levi et al., 1992;
Pellaux et al., 1992).
Notification is based on a voluntary agreement between
the recording medical institutions of the cantons and the
registries. All hospitals, pathological laboratories and most
practitioners are asked to report all new or past cases of
cancer.
Information collected by the registries includes general
demographic characteristics of the patient (age, sex,
municipality of residence), site, histological type of the
tumour, according to the standard International Classifica-
tion of Diseases for Oncology (WHO, 1976), and time of
diagnostic confirmation.
Passive and active follow-up is carried out and each
subsequent item of information concerning an already
registered case is used to complete the record of the
patient. Information obtained from the death certificate is
added to the morbidity file. Cases known only through the
death certificate ('death certificate only' cases, DCO)
contribute less than 5% of the average number of new cases
registered per year.
The registries are tumour based, and multiple primaries
occurring in the same patient are registered separately
whenever morphologically different (according to the
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pathological report) or occurring at different anatomical sites
(defined at the third-digit level of the ICD-O topographical
code; WHO, 1976). As a rule, multiple non-melanomatous
skin tumours (either synchronous or metachronous) are
classified by the site of the first recognised tumour of the
same morphological type.
For the present study, skin cancer cases were grouped into
the following three morphological categories: (1) basal cell
(ICD-O M: 8090-3, 8095-6); (2) squamous cell (ICD-O M:
8050-2, 8070-6, 8094, 8560); and (3) malignant melanoma
(ICD-O M: 8720-90, excluding 8742.2, lentigo maligna, but
including 8742.3, lentigo maligna melanoma). Other rare skin
cancers and, in particular, cancers arising from skin of genital
organs (ICD-O T: 184, 187) were excluded from the present
report. With respect to lymphoid neoplasms, we considered
all cases of non-Hodgkin's lymphoma (ICD-O M: 9590-649,
9690-709, 9740-59) and chronic lymphoid leukaemia (ICD-O
M: 9823) registered from 1974 to 1993 in the populations of
the Swiss cantons of Vaud and Neuchatel. All cases
considered in the present series were histologically verified.
Calculation of expected numbers was based on sex-, age-
and calendar year-specific incidence rates multiplied by the
observed number of person-years at risk. The end of the
follow-up was determined by a second primary, death,
emigration or the end of the study period at 31 December
1994. The significance of the observed/expected ratios
(standardised incidence ratio, SIR) was based on the Poisson
distribution applied to the observed numbers (Breslow and
Day, 1987).
Results
Table I shows the distribution of 1767 cases of NHL, 351
cases of CLL, 1678 cutaneous malignant melamomas
(CMM), 4131 squamous cell carcinomas (SCC) and 10 575
basal cell carcinomas (BCC) according to sex, mean age at
diagnosis and the person- years at risk, which were 7488
following NHL, 1820 following CLL, 10 220 following
malignant melanomas, 23 504 following squamous cell
carcinomas and 77 071 following basal cell carcinomas
(total person-years at risk 120 103).
Table II shows the observed and expected numbers of
SCC. BCC, and all skin cancers following NHL and CLL.
Only one CMM was observed following both NHL and CLL
compared with 1.2 and 0.4 expected. Overall, 36 cases of SCC
were registered following NHL compared with 5.1 expected,
corresponding to SIR of 7.0 (95% CI 4.9-9.7). The excess
Table I Selected characteristics of the study cohorts
Chronic
Non-Hodgkin's lymphocyctic Malignant Squamous Basal
lymphoma leukaemia melanoma cell carcinoma cell carcinoma
(n = 1767) (n = 351) (n = 1678) (n = 4131) (n = 10575)
No. of men 962 199 729 2219 5382
No. of women 805 152 949 1912 5193
No. of person-years 7488 1820 10220 23504 77071
Mean age at diagnosis 63.5 70.4 57.9 73.1 66.7
(years)
Mean follow-up time 4.2 5.2 6.1 5.7 7.3
(years)
Table II Observed (OBS) and expected (EXP) subsequent skin cancers, and standardised incidence ratios (SIR) of skin cancer after an initial
diagnosis of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia in the cantons of Vaud and Neuchatel, Switzerland, 1974-93
Subsequent squamous cell carcinoma Subsequent basal cell carcinoma All skin cancers?
SIR (95% confidence SIR (95% confidence SIR (95% confidence
OBS EXP interval) OBS EXP interval) OBS EXP (interval)
Non-Hodgkin's
lymphoma
Overall 36 5.1 7.0 (4.9-9.7) 37 10.2 3.6 (2.6-5.0) 74 16.6 4.5 (3.5-5.6)
By sex
Men 17 3.4 5.0 (2.9-8.0) 22 6.2 3.5 (2.2-5.4) 40 10.3 3.9 (2.8-5.3)
Women 19 2.1 9.2 (5.5-14.3) 15 4.4 3.4 (1.9-5.6) 34 7.1 4.8 (3.3-6.7)
By age at diagnosis
(years)
<75 15 0.91 16.5 (9.2-27.2) 22 3.3 6.7 (4.2-10.2) 38 4.8 7.9 (5.6-10.9)
>75 21 4.2 5.0 (3.1-7.6) 15 6.9 2.2 (1.2-3.6) 36 11.8 3.1 (2.1-4.2)
By years of follow-up
<5 22 3.3 6.6 (4.2-10.0) 20 6.6 3.1 (1.9-4.7) 43 10.7 4.0 (2.9-5.4)
>5 14 1.8 7.6 (4.2-12.8) 17 3.6 4.7 (2.7-7.5) 31 5.9 5.3 (3.6-7.5)
Chronic lymphocytic
leukaemia
Overall 9 1.8 5.0 (2.3-9.5) 9 3.3 2.7 (1.2-5.2) 19 5.5 3.5 (2.1-5.4)
By sex
Men 7 1.2 6.0 (2.4-12.3) 9 2.0 4.5 (2.1-8.6) 17 3.4 5.1 (3.0-8.1)
Women 2 0.75 2.7 (0.3-9.6) - 1.5 2 2.4 0.84 (0.1-3.0)
By age at dagnosis
(years)
<75 4 0.17 23.5 (6.3-60.2) 4 0.62 6.5 (1.7-16.5) 8 0.92 8.7 (3.7-17.1)
>75 5 1.6 3.1 (1.0-7.2) 5 2.7 1.9 (0.6-4.3) 11 4.5 2.4 (1.2-4.3)
By years of follow-up
<5 8 1.1 7.3 (3.2-14.5) 7 2.0 3.5 (1.4-7.2) 16 3.3 4.8 (2.8-7.9)
>5 1 0.72 1.4 (0.0-7.7) 2 1.3 1.6 (0.2-5.6) 3 2.1 1.4 (0.3-4.1)
aComprises basal cell and squamous cell carcinomas, and malignant melanomas (n = 2).
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was appreciably, although not significantly, larger in women
(SIR = 9.2) than in men (SIR = 5.0), but similar in strata of
duration of follow-up. When two separate age groups were
considered, risk was higher below age 75 (SIR= 16.5; 95% CI
9.2-27.2) than at age 75 or over (SIR=5.0; 95% CI 3.1-
7.6). A total of 37 cases of BCCs were observed compared
with 10.2 expected, corresponding to a SIR of 3.6 (95% CI
2.6-5.0). Significant heterogeneity was only observed across
the two separate strata of age at diagnosis considered, the
SIR being 6.7 below age 75 and 2.2 at age 75 or over. With
reference to all skin cancers, 74 cases were observed
compared with 16.6 expected (SIR=4.5, 95% CI 3.5-5.6).
Following CLL, nine cases of SCC were observed
compared with 1.8 expected (SIR= 5.0; 95% CI 2.3-9.5),
nine cases of BCC compared with 3.3 expected (SIR=2.7;
95% CI 1.2-5.2) and 19 cases of all skin cancers combined
compared with 5.5 expected (SIR=3.5; 95% CI 2.1-5.4).
The SIR was higher for men (5.1) than for women (0.8), after
shorter duration of follow-up (SIR = 4.8; <5 years vs 1.4>5
years), and for the younger age group (SIR= 8.7; <75 years
vs 2.4 > 75 years), although these differences were not
significant.
Corresponding information on lymphoid neoplasms
following major histotypes of skin cancer is shown in Table
III. After SCC, 23 cases of NHL were observed compared
with 9.0 expected (SIR=2.6; 95% CI 1.6-3.8).
No heterogeneity was observed between men and women,
across age groups or durations of follow-up. Only four cases
of CLL were observed compared with 2.7 expected and, thus,
no excess risk emerged for SCC.
A total of 43 cases of NHL were observed after BCC
compared with 22.5 expected, corresponding to a SIR of 1.9
(95% CI 1.4-2.6). With the exception of age at diagnosis, no
appreciable heterogeneity was observed across strata of sex or
durations of follow-up. After SCC, four cases of CLL were
observed compared with 2.7 expected (SIR= 1.5; 95% CI
0.4 -3.8), whereas no appreciable CLL excess was observed
after BCC (SIR= 1.1; 95% CI 0.4-2.2). After CMM, four
cases of NHL were observed (SIR = 2.0) and one case of CLL
(SIR= 1.9). None of these estimates was significant.
Discussion
The findings of this study, conducted in populations with
high standards of ascertainment, diagnosis and certification
of skin cancer (Levi et al., 1995b), confirm that there is an
excess of skin cancers (including BCC) following lymphoid
neoplasms (NHL and CLL) and an excess of NHL following
skin cancer. The relationship was observed for both SCC and
BCC, but was somewhat stronger for SCC. A consistent
pattern of risk was observed with CMM, too, but the data
were too scanty for any significant result. The lower risk of
skin cancer following CLL may be due to the low number of
cases, or may indicate a reduced association compared with
that observed with NHL.
Thus, the main contribution of this study is in showing that
not only SCC and CMM, but also BCC (which is seldom
registered in cancer registration schemes), is related to NHL
and CLL. The associations were significant and consistent for
BCC although somewhat less strong than for SCC.
Assuming that the underlying mechanism of the observed
relationship between incidence of skin cancer and lymphoid
neoplasms is U.V. radiation - and the consequent immuno-
supression of lymphoid neoplasms (Cartwright et al., 1994;
Hartge and Devesa, 1992; Doll, 1996) - this may reflect a
differential role of U.V. exposure on the incidence of SCC and
BCC. Data from the same population (Franceschi et al., 1996)
indicated that both histotypes were more common in
frequently sun-exposed areas in both sexes, although the
excess was greater for SCC. Other studies- conducted in
Denmark and Sweden (Adami et al., 1995; Hall et al., 1995)
Table In Observed (OBS) and expected (EXP) cases, and standardised incidence ratio (SIR) of subsequent non-Hodgkin's lymphoma and
chronic lymphocyctic leukaemia (CLL) after an initial diagnosis of skin cancer in the cantons of Vaud and Neuchatel, Switzerland, 1974-93
Subsequent non-Hodgkin's lymphoma
OBS EXP SIR (95% confidence inter-
val)
Subsequent chronic lymphocytic leukaemia
OBS EXP SIR (95% confidence inter-
val)
Squamous cell carcinoma
Overall
By sex
Men
Women
By age at diagnosis
(years)
<75
) 75
By years of follow-up
<5
Basal cell carcinoma
Overall
By sex
Men
Women
By age at diagnosis
(years)
<75
, 75
By years of follow-up
<5
,>5
Malignant melanoma
Overall
43 22.5
23 13.5
20 9.9
21 4.9
22 17.5
23 11.4
20 11.1
1.9 (1.4-2.6)
1.7 (1.1-2.5)
2.0 (1.2-3.1)
4.3 (2.7-6.6)
1.3 (0.8- 1.9)
2.0 (1.3-3.0)
1.8 (1.1-2.8)
7
2
3
4
4
3
6.5
4.0
2.8
0.81
5.7
3.2
3.3
1.1 (0.4-2.2)
1.2 (0.4-2.9)
0.71 (0.1-2.6)
3.7 (0.7-10.8)
0.71 (0.2-1.8)
1.3 (0.3-3.2)
0.9 (0.2-2.7)
40. 10.5)
23 9.0
11 6.0
12 3.6
4 1.1
19 7.9
13 5.6
10 3.4
2.6 (1.6-3.8)
1.8 (0.9-3.3)
3.4 (1.7- 5.9)
3.7 (1.0-9.6)
2.4 (1.4-3.8)
2.3 (1.2-4.0)
3.0 (1.4-5.4)
4
3
2
2
3
2.7
1.9
1.1
0.18
2.5
1.7
1.0
1.5 (0.4-3.8)
1.6 (0.3-4.7)
0.93 (0.0-5.2)
11.1 (1.2-40.1)
0.79 (0.1-2.8)
1.8 (0.4-5.2)
0.97 (0.0-5.4)
4 2.0 2.0 (0.5-5.0) 1 0.53 1.9 (0.0- 10.5)
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also showed a stronger association between NHL and SCC
(with SIR of the order of 5) than for CMM (SIR around or
below 2). The latter estimate was also consistent with that of a
cohort of more than 6171 cases of NHL collected in various
areas of North America and Europe (Travis et al., 1993).
A common aetiological correlate, U.V. exposure or other
factors causing immunosuppression (Cartwright et al., 1994;
Sasieni and Bataille, 1995), appears, therefore, to be a likely
explanation of the association observed. This is also
consistent with certain descriptive features of skin neoplasms
and lymphomas, including their upward trends over the last
few decades in most developed countries (Devesa and Fears,
1992; Hartge and Devesa, 1992; Carli et al., 1994; Levi et al.,
1995a,b; Hjalgrim et al., 1996) and geographic correlational
studies in the UK (Bentham, 1996; McMichael and Giles,
1996), although not in the US (Hartge et al., 1996).
Moreover, there is a lack of individual-based information
on any potential relationship between sun - and other
sources of U.V. exposure - and the risk of lymphoid
neoplasms. Before any such data are available, any inference
on aetiological correlates should be considered speculative.
Increased surveillance and diagnosis following another
neoplasm should also be considered. Although this could be a
reasonable interpretation for at least part of the skin cancer
excess following lymphoma, it is unlikely that a past history
of SCC or BCC would materially modify subsequent
ascertainment and diagnosis of lymphomas and CLL.
Furthermore, no systematic excess of any cancer sites was
observed: following skin melanoma the SIR for any site was
1.1 for men and 0.8 for women; following non-melanomas
1.0 for both; and following lymphomas 1.3 for men and 1.0
for women (Levi et al., 1993).
The absence of any clear pattern of risk with increasing
time after diagnosis of the first neoplasm is also incompatible
with a major role of ascertainment or diagnostic bias. Among
the other advantages of this study are its population basis,
the inclusion of various histotypes of skin cancer, which
should render any estimate relatively free from selection bias,
and the complete histological confirmation of the various
types of neoplasms considered.
In conclusion, therefore, this study on a population that
was particularly well surveyed for skin cancers (Levi et al.,
1995b) confirms the presence of an association between SCC,
NHL and, although less strongly, CLL. For the first time,
these data also demonstrated an association between BCC,
NHL and CLL, supporting the hypothesis that common
aetiological factors are a determinant of the increased
incidence of various types of skin and lymphoid neoplasms.
The accumulating evidence on the issue has relevance to
prevention
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